Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

Jenny Crowe(VHsquared (United Kingdom)), Michael R. West(University of Southern California)
Scientific Reports
March 15, 2018
10.1038/s41598-018-23277-7
Cited by 58

Related Papers

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
|Scientific Reports|2019|38
The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing
|PLoS Pathogens|2020|38